Chaowei Ren

Translational medicine VP

Gluetacs Therapeutics

Short Biography

Dr. Chaowei Ren has dedicated nearly eight years to the field of protein degradation, boasting profound academic expertise and industrial experience. He earned his Ph.D. from ShanghaiTech University, where he conducted research on the mechanisms of protein degraders. During his postdoctoral fellowship at the University of Chicago, he focused on post-translational modifications.

In Gluetacs Therapeutics, he is responsible for novel substrate discovery. He successfully identified over 20 new molecular glue targets, advancing the development of first-in-class drugs and driving preclinical research toward clinical translation.

Presentation Topic: GlueTacs® Molecular Glue Platform: Advancing the Discovery of Protein Degraders in Treating Cancer and Immune Diseases

• Molecular Glue Mechanisms & Substrate Characteristics; History of Gluetacs's Diversified Molecular Glue Library and R&D Pipeline.

• Molecular Glue Structural Diversity Drives Novel Substrate/Target Discovery.

• New Therapeutic Opportunities: Discovery of novel targets brings unprecedented treatment opportunities for major diseases such as cancers, autoimmune diseases, metabolic disorders, and other major diseases.